Stock Events

enGene 

$2.1
3
+$0+0% Today

Statistics

Day High
2.4
Day Low
2.1
52W High
2.4
52W Low
2.1
Volume
378
Avg. Volume
-
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

3
FEB 25
Earnings
 

Earnings

10SepExpected
Q4 2023
Q1 2024
Q2 2024
-0.46
-0.39
-0.33
-0.26
Expected EPS
-0.375279
Actual EPS
-0.32

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ENGNW. It's not an investment recommendation.
Alphabet
78260
GOOGL
Apple
68069
AAPL
Microsoft
63506
MSFT
Amazon
59244
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.99B
Vertex Pharmaceuticals focuses on developing treatments for cystic fibrosis and other diseases, overlapping with enGene's focus on gene therapy for gastrointestinal diseases.
Sangamo Therapeutics
SGMO
Mkt Cap176.57M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, which competes directly with enGene's gene therapy technologies.
CRISPR Therapeutics
CRSP
Mkt Cap4.06B
CRISPR Therapeutics is known for its work in CRISPR-Cas9 gene editing, a technology that can be applied similarly to enGene's gene delivery platforms.
Bluebird bio
BLUE
Mkt Cap108.22M
bluebird bio operates in the gene therapy space focusing on genetic diseases and cancer, areas that are potential targets for enGene's technologies.
Intellia Therapeutics
NTLA
Mkt Cap2.28B
Intellia Therapeutics is another key player in the CRISPR gene editing sector, directly competing with enGene's approach to gene therapy.
Biomarin Pharmaceutical
BMRN
Mkt Cap17.36B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, similar to enGene's market.
Alnylam Pharmaceuticals
ALNY
Mkt Cap33.72B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, a field closely related to gene therapy, impacting similar therapeutic areas as enGene.
Ionis Pharmaceuticals
IONS
Mkt Cap6.97B
Ionis Pharmaceuticals focuses on RNA-targeted drug discovery and development, competing in the broader genetic medicine space with enGene.
uniQure N.V.
QURE
Mkt Cap284.88M
uniQure is involved in developing gene therapies for patients with severe genetic diseases, directly competing with enGene's therapeutic approaches.
Regenxbio
RGNX
Mkt Cap603.95M
REGENXBIO is a biotechnology company specializing in the development of gene therapy products, competing in the same innovative sector as enGene.

About

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Show more...
CEO
Employees
31
Country
CA
ISIN
CA29286M1133

Listings

XNAS
US
ENGNW
XNAS
US
ENGN